跳至主要内容
临床试验/NCT05560620
NCT05560620已完成不适用

Impact of Sleep Deprivation on Objective, Physiological Measures of Brain Function Cognition

NeuroCatch Inc.1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2022年6月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
1
主要终点
Change in NeuroCatch® Platform 2 (NCP2), event-related potentials (ERPs) Amplitudes

研究概览

简要总结

The purpose of this study is to evaluate the measures of brain function, both neurophysiological (event-related potentials (ERPs) and functional (cognitive assessments), in response to sleep deprivation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
19 Years 至 45 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Any sex, between the ages of 19 and
  • •Able to understand the informed consent form, study procedures and willing to participate in study
  • •Able to perform the testing required by the study.
  • •Able to remain seated for 10 minutes
  • •In good health with no history of clinically relevant neurological illness, acute disease or conditions or injury in the last 5 years.
  • •A score of ≤ 5 on the Pittsburgh Sleep Quality Index (PSQI)
  • •A score between 42 and 58 on the Morningness- Eveningness Questionnaire (MEQ)
  • •Coffee consumption of < 5 cups per day.
  • •Alcohol consumption of <15 units per week.
  • •Self-described regular sleep pattern for the last 2 weeks.
  • •Willing to consume caffeine in coffee form
  • •Follow regular daily routine 24 hours prior to Baseline and between Baseline 1 and Baseline 2 study visits (i.e. sleep time, caffeine consumption etc.)

排除标准

  • •Alcohol or CBD or THC consumption 24 hours prior to baseline and during the study
  • •Currently and regularly taking sleep medications or supplements or medications that effect sleep
  • •Any health condition (e.g. chronic fatigue) that would prevent the subject from completing the required testing.
  • •Undergoing chemotherapy or any form of intensive long-term therapy.
  • •Recent (3 months) injury or other acute condition that required treatment with pain killers or analgesics.
  • •History of chronic pain or chronic headache disorders, including migraines.
  • •History of TBI or condition that affects the brain or CNS.
  • •Currently diagnosed with major psychiatric disorders (schizophrenia, bipolar, depression, generalized anxiety disorder)
  • •Diagnosed with any memory disorders.
  • •Currently diagnosed with any sleeping disorders (e.g. sleep apnea, hypersomnia, insomnia, parasomnia etc.)
  • •Recent (in the last 6 months) history of alcohol or substance misuse.
  • •Travel across time zones in the last 2 weeks.
  • •Late night or evening shift work in the last 2 weeks.
  • •Vaccination for COVID-19 within the last 72 hours prior to baseline.
  • •Currently experiencing Covid-19 symptoms, including: fever or chills, cough, tiredness/fatigue, headache, sore throat, muscle or body aches, new loss of taste or smell, congestion or runny nose, nausea or vomiting, diarrhea, difficulty breathing or shortness of breath, or chest pain.)
  • •If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding
  • •Contraindications for the NeuroCatch Platform:
  • •Requires use of hearing aids or a cochlear implant 17.
  • •Diagnosed with tinnitus that is currently active 17.
  • •Temporary damage to hearing (e.g. punctured ear drum). 17.
  • •Implanted pacemaker or implanted electrical stimulators 17.
  • •Metal or plastic implants in the skull, excluding dental/facial implants. 17.
  • •Exposed to an investigational drug or device 30 days prior to start in this study, or concurrent or planned use of investigational drug or device while enrolled in this study* 17.
  • •Not proficient in the English language 17.
  • •Diagnosed epilepsy or history of seizures 17.
  • •If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding 17.
  • •Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 17.
  • •Allergy to EEG gel

研究组 & 干预措施

Sleep Deprivation and no Caffeine intervention

Sham Comparator

Participants randomized into the sleep deprivation group and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: Sleep Deprivation (Behavioral)

Sleep Deprivation and Caffeine Intervention

Experimental

Participants randomized into the sleep deprivation group and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: Sleep Deprivation (Behavioral)

Sleep Deprivation and no Caffeine intervention

Sham Comparator

Participants randomized into the sleep deprivation group and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: No Caffeine (Other)

Control and No Caffeine

Sham Comparator

Participants randomized into the control group, who will sleep regularly, and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: No Caffeine (Other)

Control and Caffeine

Active Comparator

Participants randomized into the control group, who will sleep regularly, and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: Caffeine (Other)

Sleep Deprivation and Caffeine Intervention

Experimental

Participants randomized into the sleep deprivation group and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.

干预措施: Caffeine (Other)

结局指标

主要结局

Change in NeuroCatch® Platform 2 (NCP2), event-related potentials (ERPs) Amplitudes

时间窗: 2 days

N100, P300 and N400 amplitude values

Change in Cogstate cognitive assessment Accuracy scores from Baseline, Baseline 2 and Study Visit 3 (post-intervention)

时间窗: 2 days

accuracy (% of correct responses) scores

Change in NeuroCatch® Platform 2 (NCP2), event-related potentials (ERPs) Latencies

时间窗: 2 days

N100, P300 and N400 latency values

Change in Cogstate cognitive assessment Reaction time scores from Baseline, Baseline 2 and Study Visit 3 (post-intervention)

时间窗: 2 days

reaction time (ms) scores

次要结局

  • Demographics(1 day)
  • Safety Measures(2 days)
  • Change in NeuroCatch® Platform 2 (NCP2), event-related potentials (ERPs) pre and post caffeine intervention(1 day)
  • Change in Cogstate cognitive assessment measures (Detection Test, Identification Test, One Card Learning, and One Back Task) from Baseline, Baseline 2 and Study Visit 3 (post-intervention)(1 day)
  • Medical History(1 day)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验